Not Yet RecruitingNot Applicable

Long-term Study to Evaluate Safety and Persistence of GF-CART01

Taiwan18 participantsStarted 2026-05

Plain-language summary

The goal of this observational study is to learn about the long-term safety of GF-CART01 after cell infusion up to 15 years.

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

✓. Subjects previously enrolled in the study of GF-CART01 (Protocol No.: GF-01-01) and received GF-CART01 infusion
✓. Subjects or their legal guardians must volunteer to participate in the study and sign the informed consent
✓. Willingness and ability to comply with protocol-stated requirements, instructions, and restrictions in the investigator's judgement

Long-Term Safety of GF-CART01 after infusion

Timeframe: up to 15 years after GF-CART01 infusion

NCT IDNCT06985576

SponsorGenomeFrontier Therapeutics TW Co., Ltd.

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2041-05

Howard Cheng